Neuroinflammation in Alzheimer's, Parkinson's and Huntington's Diseases

Neuroinflammation and CNS Disorders

Volumn , Issue , 2014, Pages 111-150

  Sastre, Magdalena ^a   Katsouri, Loukia ^a   Birch, Amy ^a   Renziehausen, Alexander ^a   Dexter, David T ^a   Crichton, Robert R ^b   Ward, Roberta J ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Alzheimer's disease; Huntington's disease; Inflammation; Misfolded protein; Parkinson's disease

Indexed keywords

EID: 84947783752     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118406557.ch6     Document Type: Chapter

References (260)

1. Akiyama, H., Barger, S., Barnum, S., et al., 2000. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
2. Amara, F.M., Junaid, A., Clough, R.R., Liang, B., 1999. TGF-beta(1), regulation of alzheimer amyloid precursor protein mRNA expression in a normal human astrocyte cell line: mRNA stabilization. Molec. Brain Res. 71, 42-49.
3. Apelt, J., Ach, K., Schliebs, R., 2003. Aging-related down-regulation of neprilysin, a putative β-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of β-amyloid plaques. Neurosci. Lett. 339, 183-186.
4. Arosio, B., Trabattoni, D., Galimberti, L., Bucciarelli, P., Fasano, F., et al., 2004. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol. Aging 25, 1009-1015.
5. Banati, R. B., Goerres,G.W., Myers,R., et al., 1999. [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo inRasmussen's encephalitis. Neurology 53, 2199-2203.
6. Bard, F., Cannon, C., Barbour, R., Burke, R.L., Games, D., et al., 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916-919.
7. Bartzokis, G., 2004. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol. Aging 25, 5-18.
8. Bartzokis, G. Cummings, J., Perlman, S., Hance, D.B., Mintz, J., 1999. Increased basal ganglia iron levels in Huntington disease. Arch. Neurol. 56, 569-574.
9. Bartzokis, G., Lu, P.H., Tishler, T.A., et al., 2007. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem.Res. 32, 1655-1664.
10. Bartzokis, G., Lu, P.H., Tishler, T.A., Perlman, S., 2006. In vivo assessment of iron in Huntington's disease and other age-related degenerative brain diseases. In: A. Sigel, H. Sigel, R.K.O. Sigel (Eds.), Metal Ions in Life Sciences, vol. 1. Wiley, Chichester, UK.
11. Bartzokis, G., Tishler, T.A., 2000. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell Molec. Biol. 46, 821-833.
12. Benavides, J., Cornu, P., Dennis, T., et al., 1988. Imaging of human brain lesions with an omega 3 site radioligand. Ann. Neurol. 24, 708-712.
13. Bessler, H., Djaldetti, R., Salman, H., Bergman, M., Djaldetti, M., 1999. IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed. Pharmacother. 53, 141-145.
14. Björkqvist, M., Wild, E. J., Thiele, J., et al., 2008. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exper. Med. 205, 1869-1877.
15. Bodovitz, S., Falduto, M.T., Frail, D.E., Klein, W.L., 1995. Iron levels modulate α-secretase cleavage of amyloid precursor protein. J. Neurochem. 64, 307-315.
16. Bogdanov, M.B., Andreassen, O.A., Dedeoglu, A., Ferrante, R.J., Beal, M.F., 2001. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 79, 1246-1249.
17. Bolmont, T., Haiss, F., Eicke, D., et al., 2008. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J. Neuroscience, 28, 4283-4292.
18. Bonifati,D.M., Kishore,U., 2007.Role of complement in neurodegeneration and neuroinflammation. Molec. Immunol. 44, 999-1010.
19. Braak, H, Sastre, M, Del Tredici, K., 2007. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathologia 114, 231-241.
20. Brenner, S.R., 2005. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology, 64, 1991.
21. Breitner, J.C., Haneuse, S.J., Walker, R., et al., 2009. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72, 1899-1905.
22. Brochard, V., Combadiere, B., Prigent, A., et al., 2009. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease J. Clin. Invest. 119, 182-192.
23. Browne, T.C., McQuillan, K., McManus, R.M., et al., 2013. IFN-γ production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. J. Immunol., 190, 2241-2251.
24. Bruunsgaard, H., Andersen-Ranberg, K., Jeune, B., et al., 1999. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J. Gerontol. Ser. A Biol. Sci. Med. Sci., 54, M357-M364.
25. Bush, A.I., 2013. The metal theory of Alzheimer's disease. J. Alzheimer's Dis., 33, S277-S281. doi:10.3233/jad-2012-129011.
26. Butterfield, D.A., Swomley, A.M., Sultana, R., 2013. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signall. 19 (8), 823-835.
27. Cagnin, A, Brooks,D.J.,Kennedy, A.M. et al., 2001. In-vivo measurement of activated microglia in dementia. Lancet, 358, 461-467.
28. Carter, S.F., Schöll, M., Almkvist, O., et al., 2012. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J. Nucl. Med. 53, 37-46.
29. Castellani, R.J., Nugent, S.L., Morrison, A.L., et al., 2011. CD3 in Lexy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease? J. Neural Transmission 118: 23-26.
30. Chami, L., Checler, F., 2012. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease. Molec. Neurodegen. 7. doi: 10.1186/1750-1326-7-52.
31. Chen, C.M.,Wu,Y.R., Cheng, M.L., et al., 2007. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem. Biophys. Res. Comm. 359, 335-340.
32. Chen, M.K., Guilarte, T.R., 2008. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol. Therapeut. 118, 1-17.
33. Chen, M., Ona, V. O., Li, M., et al., 2000. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6, 797-801.
34. Choi, D.W., 2005. Neurodegeneration: cellular defences destroyed. Nature 433, 696-698.
35. Choi, Y., Kim, H.-S., Shin, K.Y., et al., 2007. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32, 2393-2404.
36. Collins, L.M., 2012. Contribution of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology, 62, 2154-2168.
37. Combarros, O., van Duijn, C.M., Hammond, N., et al., 2009. Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. J. Neuroinflamm. 6, 22.
38. Combs, C.K., Karlo, J.C., Kao, S.C., Landreth, G.E., 2001. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 21, 1179-1188.
39. Cornett, C.R., Markesbery, W.R., Ehmann, W.D., 1998. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 19, 339-345.
40. Cosenza-Nashat, M., Zhao, M.L., Suh, H.S., et al., 2009. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol. Appl. Neurobiol. 35, 306-328.
41. Couch, Y., Alvarez-Erviti, L., Sibson, N.R., Wood, M.J.A., Anthony, D.C., 2011. The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J. Neuroinflamm. 8, 166-180.
42. Crichton, R., Dexter, D., Ward, R., 2011. Brain iron metabolism and its perturbation inneurological diseases. J. Neural Trans. 118, 301-314.
43. Crichton, R.R., Ward, R.J., 2006. Metal Based Neurodegeneration: From Molecular Mechanisms to Therapeutic Strategies. JohnWiley and Sons, Chichester, UK.
44. Crichton, R.R., Ward, R.J., 2013. Metal Based Neurodegeneration: From Molecular Mechanisms to Therapeutic Strategies, 2nd ed. John Wiley and Sons, Chichester, UK.
45. Dalrymple, A., Wild, E.J., Joubert, R., et al., 2007. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 6, 2833-2840.
46. De Luca,G.,Russo, M.T., Degan, P., et al., 2008.Arole for oxidizedDNAprecursors in Huntington's disease-like striatal neurodegeneration. PLoS Genetics 4, e1000266.
47. del Hoyo, P., García-Redondo, A., et al., 2006. Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease. Neurochem. Res. 31, 1103-1109.
48. Dexter,D.T., 2013. Parkinson's disease. In: R.J.Ward, R.R. Crichton, andD.T. Dexter (Eds.), Mechanisms and Metal Involvement in Neurodegenerative Diseases. Royal Society of Chemistry, London, pp. 1-213.
49. Dexter, D.T., Jenner, P., 2013. Parkinson disease: from pathology to molecular disease mechanisms. Free Rad. Biol. Med. 62, 132-144.
50. Dexter, D.T., Jenner, P., Schapira, A.H., Marsden, C.D., 1992. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 32 (Suppl. 1), S94-S100.
51. Dheen, S.T., Kaur, C., Ling, E.A., 2007. Microglial activation, and its implications in the brain diseases. Curr. Med. Chem. 14, 1189-1197.
52. Di Bona, D., Rizzo, C., Bonaventura, G., Candore, G., Caruso, C., 2012. Association between interleukin-10 polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimer's Dis. 29, 751-759.
53. Dickson, D.W., Lee, S.C., Mattiace, L.A., Yen, S.H., Brosnan, C., 1993. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia, 7, 75-83.
54. Dill, J., Patel, A.R., Yang, X.L., Bachoo, R., Powell, C.M., Li, S., 2010. A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J. Neurosci. 30, 963-972.
55. Ding, B., Chen, K.-M., Ling, H.-W., et al., 2009. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease. J. Magn. Reson. Imag. 29, 793-798.
56. Du, Y., Dodel, R.C., Eastwood, B.J., et al., 2000. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology, 55, 480-483.
57. Dumas, E.M., Versluis, M.J., van den Bogaard, S.J., 2012. Elevated brain iron is independent from atrophy in Huntington's disease. Neuroimage 61, 558-564.
58. El Khoury, J., Luster, A.D., 2008. Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci. 29, 626-632.
59. Falsig, J., van Beek, J., Hermann, C., Leist, M., 2008. Molecular basis for detection of invading pathogens in the brain. J. Neurosci. Res. 86, 1434-1447.
60. Familian, A., Boshuizen, R.S., Eikelenboom, P., Veerhuis, R., 2006. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia 53, 233-240.
61. Farina, C., Aloisi, F., Meinl, E., 2007. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 28, 138-145.
62. Faulkner, J.R., 2004. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J. Neurosci. 24, 2143-2155.
63. Ferretti, M.T., Allard, S., Partridge, V., et al., 2012. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. J. Neuroinflamm. 9, 62.
64. Festuccia, W.T., Oztezcan, S., Laplante, M., et al., 2008. Peroxisome proliferatoractivated receptor-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology 149, 2121-2130.
65. Fillit, H., Ding,W.H., Buee, L., Kalman, J., Altstiel, L., Lawlor,B., et al., 1991. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129, 318-320.
66. Forder, J.P., Tymianski, M., 2009. Postsynaptic mechanisms of excitotoxicity: involvement of postsynaptic density proteins, radicals, and oxidant molecules. Neuroscience 158, 293-300.
67. Frautschy, S.A., Yang, F., Irrizarry, M. et al., 1998. Microglial response to amyloid plaques in APPsw transgenic mice. Amer. J. Pathol. 152, 307-317.
68. Frenkel, D., Maron, R., Burt, D.S., Weiner, H.L., 2005. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 115, 2423-2433.
69. Furuta, A., Price,D.L., Pardo, C.A., et al., 1995. Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Amer. J. Pathol. 146, 357-367.
70. Games, D., Adams, D., Alessandrini, R., et al., 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523-527.
71. Gao, H.M., Hong, J.S., 2008. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 29, 357-365.
72. Gegg, M.E., Beltran, B., Salas-Pino, S., et al., 2003. Differential effect of nitric oxide on GSH metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/ neurodegeneration? J. Neurochem. 86, 228-237.
73. Gerhard, A., Pavese, N., Hotton, G., et al., 2006. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21, 404-412.
74. Ghosh, S., Wu, M.D., Shaftel, S.S., et al., 2013. Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J. Neurosci. 33, 5053-5064.
75. Giasson, B.I., Duda, J.E., Murray, I.V., et al., 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985-989.
76. Gomez-Tortosa, E., MacDonald, M.E., Friend, J.C., et al., 2001. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann. Neurol. 49, 29-34.
77. Gotz, M.E., Double, K., Gerlach, M., Youdin, M.B., Riederer, P., 2004. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. NY Acad. Sci. 1012, 193-208.
78. Griffin, W.S., Mrak, R.E., 2002. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J. Leuko. Biol. 72, 233-238.
79. Griffin, W.S., Nicoll, J.A., Grimaldi, L.M., Sheng, J.G., Mrak, R.E., 2000. The pervasiveness of interleukin-1 in Alzheimer pathogenesis: a role for specific polymorphisms in disease risk. Exper. Gerontol. 35, 481-487.
80. Griffin, W.S., Sheng, J.G., Roberts, G.W., Mrak, R.E., 1995. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exper. Neurol. 54, 276-281.
81. Griffin, W.S., Stanley, L.C., Ling, C., et al., 1989. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA 86, 7611-7615.
82. Grimaldi, L.M., Casadei, V.M., Ferri, C., et al., 2000. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann. Neurol. 47, 361-365.
83. Guglielmotto, M., Giliberto, L., Tamagno, E., Tabaton, M., 2010. Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front. Aging Neurosci. 2.
84. Guidetti, P., Charles, V., Chen, E.Y., et al., 2001. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exper. Neurol. 169, 340-350.
85. Guo, J.T., Yu, J., Grass, D., de Beer, F.C., Kindy, M.S., 2002. Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J. Neurosci. 22, 5900-5909.
86. Hacker, H., Karin, M., 2006.Regulation and function of IKK and IKK-related kinases. Sci. Signall. 357, re13.
87. Hafer-Macko, C.E., Dyck, P.J., Koski, C.L., 2000. Complement activation in acquired and hereditary amyloid neuropathy. J. Peripher. Nerv. Syst. 5, 131-139.
88. Hanyu, H., Sato, T., Kiuchi, A., et al., 2009. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J. Amer. Geriatric Soc. 57, 177-179.
89. Haque, N.S., Borghesani, P., Isacson,O., 1997. Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder. Molec. Med. Today 3, 175-183.
90. Hayden, K.M., Zandi, P.P., Khachaturian, A.S., et al., 2007. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 69, 275-282.
91. Hayes, A., Green, E.K., Pritchard, A., et al., 2004. A polymorphic variation in the interleukin 1A gene increases brain microglial cell activity in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1475-1477.
92. Helmy, A.A., Naseer, M.M., Shafie, S., Nada, M.A., 2012. Role of interleukin 6 and alpha-globulins in differentiating Alzheimer and vascular dementias. Neurodegen. Dis. 9 (2), 81-86.
93. Heneka, M.T., Sastre, M., Dumitrescu-Ozimek, L., et al., 2005. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J. Neuroinflamm. 2, 22.
94. Hernandes, M.S., Britto, L.R., 2012. NADPH oxidase and neurodegeneration. Curr. Neuropharmacol. 10, 321-327.
95. Hickman, S.E., Allison, E.K., El Khoury, J., 2008. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neuroscience 28, 8354-8360.
96. Hunot, S., Dugas, N., Faucheux, B., et al., 1999. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci. 19, 3440-3447.
97. Hwang, O., 2013. Role of oxidative stress in Parkinson's disease. Exper. Neurobiol. 22, 11-17.
98. Imamura, K., Hishikawa, N., Sawada, M., et al., 2003. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathology 106, 518-526.
99. Janelsins, M.C., Mastrangelo, M.A., Oddo, S., et al., 2005. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J. Neuroinflamm. 2, 23.
100. Janelsins, M.C., Mastrangelo, M.A., Park, K.M., et al., 2008. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Amer. J. Pathol. 173, 1768-1782.
101. Jimenez, S., Baglietto-Vargas, D., Caballero, C., et al., 2008. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic J. Neurosci. 28, 11650-11661.
102. Karuppagounder, S.S., Xu, H., Shi, Q., et al., 2009. Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol. Aging 30, 1587-1600.
103. Kato, S., Gondo, T., Hoshii, Y., et al., 1998. Confocal observation of senile plaques in Alzheimer's disease: senile plaque morphology and relationship between senile plaques and astrocytes. Pathol. Intl. 48, 332-340.
104. Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devilliers, A., Cayrol, R., et al., 2007. Human Th17 lymphocytes promote blood brain barrier disruption and central nervous system inflammation. Nature Med. 13, 1173-1175.
105. Keene, C.D., Cudaback, E., Li, X., Montine, K.S., Montine, T.J., 2011. Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease. Curr. Opin. Neurobiol. 21, 920-928.
106. Khoshnan, A., Ko, J.,Watkin, E.E., et al., 2004.Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci. 24, 7999-8008.
107. Khoshnan, A., Patterson, P.H., 2011. The role of IκB kinase complex in the neurobiology of Huntington's disease. Neurobiol. Dis. 43, 305-311.
108. Kiyota, T., Ingraham, K.L., Swan, R.J., et al., 2012. AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther. 19, 724-733.
109. Klepac, N., Relja, M., Klepac, R., et al., 2007. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study. J. Neurol. 254, 1676-1683.
110. Kobayashi, K., Imagama, S., Ohgomor, T., Hirano, K., et al., 2013. Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis. 4, e525.
111. Koenigsknecht-Talboo, J., Meyer-Luehmann, M., Parsadanian, M., et al., 2008. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J. Neurosci. 28, 14156-14164.
112. Koistinaho, M., Lin, S.,Wu, X., et al., 2004. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nature Med. 10, 719-726.
113. Kosloski, L.M., Ha, D.M., Huttler, J.A., et al., 2010. Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J. Neurochem. 114, 261-276.
114. Kummer, M.P., Hermes, M., Delekarte, A., et al., 2011. Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. Neuron 71, 833-844.
115. Leal, M.C., Casabona, J.C., Puntel, M., Pitossi, F.J., 2013. Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's disease? Front. Cell. Neurosci. doi:10.3389/fncel.2013.00053.
116. Lee, Y.B., Nagai, A., Kim, S.U., 2002. Cytokines, chemokines, and cytokine receptors in human microglia. J. Neurosci. Res. 69, 94-103.
117. Lee Mosley, R., Hutter-Saunders, J.A., Stine, D.K., Gendelman, H.E., 2012. Inflammation and Adaptive Immunity in Parkinson's Disease. Cold Spring Harbor Persp. Med. 2 (1), a009381. doi: 10.1101/cshperspect.a009381.
118. Levesque, S.,Wilson,B., Gregoria,V., Thorpe, L.B., 2010.Reactive microgliosis: extracellular micro-calpain. Brain 133, 808-821.
119. Li, C., Zhao, R., Gao, K., et al., 2011. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 8, 67-80.
120. Li, R., Yang, L., Lindholm, K., et al., 2004. Tumor necrosis factor death receptor signaling cascade is required for amyloid-β protein-induced neuron death. J. Neurosci. 24, 1760-1771.
121. Liu, B., Hong, J.-S., 2003.Role of Microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exper. Ther. 304, 1-7.
122. Ma, L., Nicholson, L.F., 2004. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Brain Res. 1018, 10-17.
123. Maksimović, I.D., Jovanović, M.D., Colić, M., et al., 2001. Oxidative damage and metabolic dysfunction in experimental Huntington's disease: selective vulnerability of the striatum and hippocampus. Vojnosanitetski pregled. 58, 237-242.
124. Mandrekar, S., Jiang, Q., Lee, C.Y., et al., 2009. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J. Neurosci. 29, 4252-4262.
125. Mandrekar-Colucci, S., Karlo, J.C., Landreth, G.E., 2012. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J. Neurosci. 32, 10117-10128.
126. Maragakis, N.J., Rothstein, J.D., 2006. Mechanisms of disease: astrocytes in neurodegenerative disease. Nature Clin. Prac. Neurol. 2, 679-689.
127. Marinova-Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J.B., Medhurst, A.D., Dexter, D.T., 2009. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J. Neurochem. 110, 966-975.
128. Mark, R.J., Pang, Z., Geddes, J.W., et al., 1997. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. 17, 1046-1054.
129. Matsuoka, Y., Picciano, M., La Francois, J., Duff, K., 2001. Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience 104, 609-613.
130. McGeer, E.G., Singh, E.A., McGeer, P.L., 1998a. Peripheral-type benzodiazepine binding in Alzheimers disease. Alzheimer Dis. Assoc. Disorders 2, 331-336.
131. McGeer, P.L., Itagaki, S., Boyes, B.E., McGeer, E.G., et al., 1998b. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291.
132. McGeer, P.L., Itagaki, S., McGeer, E.G., 1988. Expression of the histocompatibility glycoproteinHLA-DR in neurological disease.Acta Neuropathologica 76, 550-557.
133. McGeer, P.L, McGeer, E.G., 1998. Mechanisms of cell death in Alzheimer disease -immunopathology. J. Neural Trans. 54 (Suppl.), 159-166.
134. McTigue, D.M., Tripathi, R.B., 2008. The life, death, and replacement of oligodendrocytes in the adult CNS. J. Neurochem. 107, 1-19.
135. Mecocci, P., 2004. Oxidative stress in mild cognitive impairment and Alzheimer disease: a continuum. J. Alzheimer's Dis. 6, 159-163.
136. Meda, L., Cassatella, M.A., Szendrei, G.I., et al., 1995. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374, 647-650.
137. Medeiros, R., LaFerla, F.M., 2013. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exper. Neurol. 239, 133-138.
138. Mehlhorn, G., Hollborn, M., Schliebs, R., 2000. Induction of cytokines in glial cells surrounding cortical β-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. International J. Devel. Neurosci. 18, 423-431.
139. Messmer, K., Reynolds, G.P., 1998. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. Neurosci. Lett. 241, 53-56.
140. Meyer-Luehmann, M., Spires-Jones, T.L., Prada, C., et al., 2008. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451, 720-724.
141. Milnerwood, A.J., Raymond, L.A., 2010. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 33, 513-523.
142. Mirza, B., Hadberg, H., Thomsen, P., Moos, T., 2000. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95, 425-432.
143. Moller, K., 2010. Neuroinflammation in Huntington's disease. J. Neural. Trans. 117, 1001-1008.
144. Montgomery, S.L., Narrow, W.C., Mastrangelo, M.A., et al., 2013. Chronic neuronand age-selective down-regulation of TNF receptor expression in triple-transgenic Alzheimer disease mice leads to significant modulation of amyloid- and tau-related pathologies. Amer. J. Pathol. 182, 2285-2297.
145. Morgan, M.J., Liu, Z-G., 2011. Crosstalk of reactive oxygen species and NFkB signalling. Cell Res. 21, 103-115.
146. Morris, C.M., Kerwin, J.M., Edwardson, J.A., 1994. Non-haem iron histochemistry of the normal and Alzheimer's disease hippocampus. Neurodegeneration 3, 267-275.
147. Mrak, R.E., Griffin,W.S.T., 2005. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 26, 349-354.
148. Myer, D.J., 2006. Essential protective roles of reactive astrocytes in traumatic brain injury. Brain 129, 2761-2772.
149. Myers, R.H., Vonsattel, J.P., Paskevich, P.A., et al., 1991. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J. Neuropathol. Exper. Neurol. 50, 729-742.
150. Mythri, R.B., Venkateshappa, C., Harish, G., et al., 2011. Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem. Res. 36, 1452-1263.
151. Niranjan, R., 2013. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes. Molec. Neurobiol. June 20. [Epub ahead of print].
152. Noble, W., Garwood, C., Stephenson, J. et al., 2009. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 23, 739-750.
153. Nolan, Y.M., Sullivan, A.M., Toulouse, A., 2013. Parkinson's disease in the nuclear age of neuroinflammation. Trends Molec. Med. 19, 187-196.
154. Nunomura, A., Perry, G., Aliev, G., et al., 2001. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exper. Neurol. 60, 759-767.
155. Nunomura, A., Perry, G., Pappolla, M.A., Wade, R., et al., 1999. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19, 1959-1964.
156. Okello, A., Edison, P., Archer, H.A., et al., 2009. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 72, 56-62.
157. Ouchi, Y., Yoshikawa, E., Sekine, Y., et al., 2005. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57, 168-175.
158. Pappolla, M.A., Chyan, Y.J., Omar, R.A., et al., 1998. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Amer. J. Pathol. 152, 871-877.
159. Pavese, N., Gerhard, A., Tai, Y.F., et al., 2006. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66, 1638-1643.
160. Pérez-Severiano, F., Ríos, C., Segovia, J., 2000. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. 862, 234-237.
161. Peters, A., Sethares, C., 2004. Oligodendrocytes, their progenitors and other neuroglial cells in the aging primate cerebral cortex. Cereb. Cortex 14, 995-1007.
162. Pihlaja, R., Koistinaho, J., Kauppinen, R., Sandholm, J., Tanila, H., Koistinaho, M., 2011. Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes. Glia 59, 1643-1657.
163. Pihlaja, R.,Koistinaho, J., Malm, T., Sikkilä, H.,Vainio, S.,Koistinaho, M., 2007. Transplanted astrocytes internalize deposited β-amyloid peptides in a transgenic mouse model of Alzheimer's disease. Glia 56, 154-163.
164. Pike, V.W., Halldin, C., Crouzel, C., et al., 1993. Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites -current status. Nuclear Med. Biol. 20, 503-525.
165. Polazzi, E., Monti, B., 2010. Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog. Neurobiol. 92, 293-315.
166. Politis, M., Pavese, N., Tai, Y.F., et al., 2008. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 131, 2860-2869.
167. Politis, M., Pavese, N., Tai, Y.F., et al., 2011. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Human Brain Mapping 32, 258-270.
168. Praticò, D., Clark, C.M., Lee, V.M., Trojanowski, J.Q., et al., 2000. Increased 8,12-isoiPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48, 809-812.
169. Praticò, D., Clark, C.M., Liun, F., et al., 2002. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 59, 972-976.
170. Praticò,D., Uryu, K., Leight, S. et al., 2001. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21, 4183-4187.
171. Qiu, W.Q., Walsh, D.M., Ye, Z., et al., 1998. Insulin-degrading enzyme regulates extracellular levels of amyloid b-protein by degradation. J. Biol. Chem. 273, 32730-32738.
172. Qiu, W.Q., Ye, Z., Kholodenko, D., Seubert, P., Selkoe, D.J., 1997. Degradation of amyloid b-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem. 272, 6641-6646.
173. Qureshi, G.A., Baig, S., Bednar, I. et al., 1995. Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease Neuroreport 6, 1642-1644.
174. Raivich, G., 2005. Like cops on the beat: the active role of resting microglia. Trends Neurosci. 28, 571-573.
175. Ransohoff, R.M., Perry, V.H., 2009. Microglial physiology: unique stimuli, specialized responses. Ann. Rev. Immunol. 27, 119-145.
176. Rappold, P.M., Tieu, K., 2010. Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 7, 413-423.
177. Rauert, H., Wicovsky, A., Muller, N., et al., 2010. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J. Biol. Chem. 285, 7394-7404.
178. Rebeck, G.W., 2000. Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease. Neurosci. Lett. 293, 75-77.
179. Reed-Geaghan, E.G., Savage, J.C., Hise, A.G., Landreth, G.E., 2009. CD14 and tolllike receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J. Neurosci. 29, 11982-11992.
180. Rice, M.E., Russo-Menna, I., 1998. Differential compartmentalization of brain ascorbate and GSH between neurons and glia. Neuroscience 82, 1213-1223.
181. Rivera-Mancía, S., Pérez-Neri, I., Ríos, C., Tristán-López, L., Rivera-Espinosa, L., Montes, S., 2010. The transition metals copper and iron in neurodegenerative diseases. Chemico- Biol. Inter. 186, 184-199.
182. Rodríguez, J.J., Olabarria, M., Chvatal, A.,Verkhratsky, A., 2009. Astroglia in dementia and Alzheimer's disease. Cell Death Differ. 16, 378-385.
183. Rogers, J.T., Leiter, L.M., McPhee, J., et al., 1999. Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J. Biol. Chem. 274, 6421-6431.
184. Rogers, J. Luber-Narod, J. Styren, S.D., Civin, W.H., 1988. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol. Aging 9, 339-349.
185. Rogers, J.T., Randall, J.D., Cahill, C.M., et al., 2002. An iron-responsive element Type II in the 5′ -untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277, 45518-45528.
186. Rohn, T.T., Catlin, L.W., 2011. Immunolocalization of influenza A virus and markers of inflammation in the human Parkinson's disease brain. PloS One 6, e20495.
187. Rus, H., Cudrici, C., David. S., Niculescu, F., 2006. The complement system in central nervous system diseases. Autoimmunity 39, 395-402.
188. Ryu, J.K., Franciosi, S., Sattayaprasert, P., Kim, S.U., McLarnon, J.G., 2004. Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia 48, 85-90.
189. Salman, H., Bergman, M., Djaldetti, R., Bessler, H., Djaldetti, M., 1999. Decreased phagocytic function in patients with Parkinson's disease. Biomed. Pharmacother. 53, 146-148.
190. Salminen, A., Ojala, J., Kauppinen, A., Kaarniranta, K., Suuronen, T., 2009. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 87, 181-194.
191. Sapp, E., Kegel, K.B., Aronin, N., et al., 2001. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exper. Neurol. 60, 161-172.
192. Sastre, M., Dewachter, I., Landreth,G.E., et al., 2003. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 23, 9796-9804.
193. Sastre, M., Dewachter, I., Rossner, S., et al., 2006a. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. USA 103, 443-448.
194. Sastre, M., Gentleman, S.M., 2010. NSAIDs: how they work and their prospects as therapeutics in Alzheimer's disease. Front Aging Neurosci. 2, 20.
195. Sastre, M., Klockgether, T., Heneka, M.T., 2006b. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Intl. J. Devel. Neurosci. 24, 167-176.
196. Sastre, M., Walter, J., Gentleman, S.M., 2008. Interactions between APP secretases and inflammatory mediators. J. Neuroinflamm. 5, 25.
197. Sayre, L.M., Zelasko, D.A., Harris, P.L., et al., 1997. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68, 2092-2097.
198. Scarf, A.M., Ittner, L.M., Kassiou, M., 2009. The translocator protein (18 kDa): central nervous system disease and drug design. J. Med. Chem. 52, 581-592.
199. Schapira, A.H., Cooper, J.M., Dexter, D., et al., 1990. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827.
200. Schilling, G., Coonfield, M.L., Ross, C.A., Borchelt, D.R., 2001. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 315, 149-153.
201. Seabrook, T.J., Jiang, L., Maier, M., Lemere, C.A., 2006. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 53, 776-782.
202. Shaftel, S.S., Carlson, T.J., Olschowka, J.A., Kyrkanides, S., Matousek, S.B., O'Banion, M.K., 2007. Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J. Neurosci. 27, 9301-9309.
203. Shen, Y., Meri, S., 2003. Yin and yang: complement activation and regulation in Alzheimer's disease. Prog. Neurobiol. 70, 463-472.
204. Sheng, J.G., Ito, K., Skinner, R.D., et al., 1996. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol. Aging 17, 761-766.
205. Sheng, J.G., Zhu, S.G., Jones, R.A., Griffin,W.S., Mrak, R.E., 2000. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exper. Neurol. 163, 388-391.
206. Sherwood, C.C., Stimpson, C.D., Raghanti, M.A., et al., 2006. Evolution of increased glia-neuron ratios in the human frontal cortex. Proc. Natl. Acad. Sci. USA 103, 13606-13611.
207. Shi, J.Q., Shen, W., Chen, J., Wang, B.R., et al., 2011. Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 1368, 239-247.
208. Sian, J., Dexter, D.T., Lees, A.J., et al., 1994. Alterations in GSH levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348-355.
209. Silvestri, L., Camaschella, C., 2008. A potential pathogenetic role of iron in Alzheimer's disease. J. Cell. Molec. Med. 12, 1548-1250.
210. Silvestroni, A., Faull, R.L., Strand, A.D., Moller, T., 2009. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 20, 1098-1103.
211. Simmons, D.A., Casale, M., Alcon, B., et al., 2007. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 55, 1074-1084.
212. Simpson, J.E., Ince, P.G., Lace, G., Forster, G., Shaw, P.J., Matthews, F., et al., 2010. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol. Aging 31, 578-590.
213. Singhrao, S.K., Neal, J.W., Morgan, B.P., Gasque, P., 1999. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exper. Neurol. 159, 362-376.
214. Smith, M.A., Hirai, K., Hsiao, K. et al., 1998. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70, 2212-2215.
215. Smith, M.A., Kutty, R.K., Richey, P.L., et al., 1994. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Amer. J. Pathol. 145, 42-47.
216. Smith, M.A., Richey Harris, P.L., Sayre, L.M., et al., 1997. Widespread peroxynitritemediated damage in Alzheimer's disease. J. Neurosci. 17, 2653-2657.
217. Sofroniew, M.V., 2009. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32, 638-647.
218. Solito, E., Sastre, M., 2012. Microglia and Alzheimer's disease. Front. Neuropharmacol. 3, 14.
219. Sotrel, A., Paskevich, P.A., Kiely, D.K., et al., 1991. Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 41, 1117-1123.
220. Stack, E.C., Matson,W.R., Ferrante, R.J., 2008. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann. NY Acad. Sci. 1147, 79-92.
221. Stack, E.C., Smith, K.M., Ryu, H., et al., 2006. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochimica Biophysica Acta 1762, 373-380.
222. Stoy, N., Mackay, G.M., Forrest, C.M., et al., 2005. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem. 93, 611-623.
223. Streit, W., Braak. H., Xue, Q.S., Bechmann, I., 2009. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathologica 118, 475-485.
224. Streit, W.J., Sammons, N.W., Kuhns, A.J., Sparks, D.L., 2004. Dystrophic microglia in the aging human brain. Glia 45, 208-212.
225. Szydlowska, K., Tymianski, M., 2010. Calcium, ischemia and excitotoxicity. Cell Calcium 47, 122-129.
226. Tai, Y.F., Pavese, N., Gerhard, A., et al., 2007. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 130, 1759-1766.
227. Tamagno, E., Bardini, P., Obbili, A., et al., 2002. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 10, 279-288.
228. Tamagno, E., Guglielmotto, M., Aragno, M., et al., 2008. Oxidative stress activates a positive feedback between the γ- and β-secretase cleavages of the β-amyloid precursor protein. J. Neurochem. 104, 683-695.
229. Tamagno, E., Guglielmotto, M., Bardini, P., et al., 2003. Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. Neurobiol. Dis. 14, 291-301.
230. Tamagno, E., Guglielmotto, M., Monteleone, D., Tabaton, M., 2012. Amyloid-β production: major link between oxidative stress and BACE1. Neurotox. Res. 22, 208-219.
231. Tan, J.-L., Li, Q.-X., Ciccotosto, G.D., Crouch, P.J., et al., 2013. Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer's disease amyloid precursor protein. PLoS One, 8 (4), e61246.
232. Tarkowski, E., Blennow, K.,Wallin, A., Tarkowski, A., 1999. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J. Clin. Immunol. 19, 223-230.
233. Taylor, J.M., Main, B.S., Crack, P.J., 2013. Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson's disease. Neurochem. Intl. 62, 803-819.
234. Terwel, D., Steffensen, K.R., Verghese, P.B. et al., 2011. Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. J. Neurosci. 31, 7049-7059.
235. Thal, D.R., Schober, R., Birkenmeier, G., 1997. The subunits of alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein, native and transformed alpha2-macroglobulin and interleukin 6 in Alzheimer's disease. Brain Res., 777, 223-227.
236. Thal, D.R., Schultz, C., Dehghani, F., et al., 2000. Amyloid beta-protein (Abeta)-containing astrocytes are located preferentially near N-terminal-truncated Abeta deposits in the human entorhinal cortex. Acta Neuropathologica 100, 608-617.
237. Valencia, A. Reeves, P.B., Sapp, E., 2010. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease. J. Neurosci. Res. 88, 179-190.
238. Valencia, A., Sapp, E., Kimm, J.S., et al., 2013. Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease. Human Molec. Gen. 22, 1112-1131.
239. Van Dam, D., Vloeberghs, E., Abramowski, D., Staufenbiel, M., De Deyn, P., 2005. APP23 mice as a model of Alzheimer's disease: an example of a transgenic approach to modeling a CNS disorder. CNS Spectrums 10, 207-222.
240. Varvel, N.H., Bhaskar, K., Kounnas, M.Z., Wagner, S.L., Yang, Y., Lamb, B.T., et al., 2009. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J. Clin. Invest. 119, 3692-3702.
241. Verkhratsky, A., Olabarria, M., Noristani, H.N., Yeh, C.-Y., Rodriguez, J.J., 2010. Astrocytes in Alzheimer's disease. Neurotherapeutics 7, 399-412.
242. Vitale, G., Salvioli, S., Franceschi, C., 2013. Oxidative stress and the ageing endocrine system. Nature Rev. Endocrin. 9, 228-240.
243. vom Berg, J., Prokop, S., Miller, K.R., et al., 2012. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nature Med. 18, 1812-1819.
244. Vonsattel, J.P, DiFiglia, M., 1998. Huntington disease. J. Neuropathol. Exper. Neurol. 57, 369-384.
245. Vonsattel, J.P., Myers, R.H., Stevens, T.J., et al., 1985. Neuropathological classification of Huntington's disease. J. Neuropathol. Exper. Neurol. 44, 559-577.
246. Ward, R.J., Crichton, R.R., Taylor,D.L., Della Corte, L., Srai, S.K., Dexter,D.T., 2011. Iron and the immune system. J. Neural Trans. 118, 315-328.
247. Watts, J.C., Giles, K., Grillo, S.K., Lemus, A., DeArmond, S.J., Prusiner, S.B., 2011. Bioluminescence imaging ofAβ deposition in bigenic mouse models of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 108, 2528-2533.
248. Whitton, P.S., 2007. Inflammation as a causative factor in the aetiology of Parkinson's disease. Brit. J. Pharmacol. 150, 963-976.
249. Wild, E., Magnusson, A., Lahiri, N., et al., 2011. Abnormal peripheral chemokine profile in Huntington's disease. PloS Curr. 3, RRN1231.
250. Wu, D.C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., et al., 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771.
251. Wyss-Coray, T., 2006. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nature Med. 12, 1005-1015.
252. Wyss-Coray, T., Loike, J.D., Brionne, T.C., et al., 2003.Adult mouse astrocytes degrade amyloid-β in vitro and in situ. Nature Med. 9, 453-457.
253. Yamanaka, M., Ishikawa, T., Griep, A., et al., 2012. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J. Neuroscience. 32, 17321-17331.
254. Yan, S.D., Yan, S.F., Chen, X., et al., 1995. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nature Med. 1, 693-699.
255. Yang, L., Lindholm, K., Konishi, Y., Li, R., Shen, Y., 2002. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J. Neurosci. 22, 3025-3032.
256. Yoshiyama, Y., Higuchi, M., Zhang, B., et al., 2007. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351.
257. Zecca, L., Youdim, M.B., Riederer, P., Connor, J.R., Crichton, R.R., 2004. Iron, brain ageing and neurodegenerative disorders. Nature Rev. Neurosci. 5, 863-873.
258. Zhang, W., Wang, T., Pei, Z., et al., 2005. Aggregated alpha synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19, 533-542.
259. Zhu, S., Stavrovskaya, I.G., Drozda, M., et al., 2002. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74-78.
260. Zuccato, C., Cattaneo, E., 2010. Molecular mechanisms and potential therapeutic targets in Huntington's disease. Physiol. Rev. 90, 905-981.